Isracann Biosciences Inc. - CEO, Phil Floucault
CEO, Phil Floucault
Source: Cowichan Valley Citizen
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Isracann Bioscience (IPOT) announces that its first shipment of cannabis strains has cleared Israeli customs
  • The three strains shipped are called: Liberty Haze, Hell Monkey, and Grape Stomper
  • Canadian quality cannabis will soon be grown in Israel and available to Israeli customers
  • Isracann engages in the cultivation, manufacturing, distribution, and branding of medical cannabis-based products
  • Isracann Biosciences Inc. (IPOT) opened trading at C$0.045

Isracann Bioscience (IPOT) announces that its first shipment of cannabis strains has cleared Israeli customs and are being raised as mother stock.

“The Israeli market will now have access to premium Canadian high THC genetics,” notes CEO Phil Floucault.

“The three strains we shipped are called: Liberty Haze, Hell Monkey, and Grape Stomper. All three strains have received a positive response from consumers in Canada, and I am looking forward to being able to make them available to the Israeli market.”

The three strains sent were developed as part of United Greeneries’ “Grass Roots” genetics program, which aims to produce novel high THC strains with commercially high yields.

Currently being sold as premium cannabis flower in Canada, the three strains represent some of the top performing genetics in United Greeneries’ catalogue. With the support of United Greeneries and Isracann, all three strains have been integrated into the Intelicanna facility and are being prepared as the initial Israeli mother stock.

Phil Floucault continues, “The planning and preparation by the teams in Canada and Israel made this genetics shipment happen smoothly. The growing teams are now fully engaged and working to expedite the process of scaling to full production. In the near term, Canadian quality cannabis will be grown in Israel and available to Israeli customers. Canadian genetics, Israeli grown.”

Isracann engages in the cultivation, manufacturing, distribution, and branding of medical cannabis-based products.

Isracann Biosciences Inc. (IPOT) opened trading at C$0.045.


More From The Market Herald

Buzz on the Bullboards: Has the November rally paid off?

In the past week, the energy sector has been leading downward pressure on Canada’s main stock index as crude oil prices continued to fall.

Canopy Growth’s new CBD gummies follow cannabis wellness trend

Canopy Growth is debuting a new line of Martha Stewart CBD gummies set to benefit from a consumer shift to cannabis wellness solutions.

What is going on with Canopy Growth stock?

Canopy Growth (TSX:WEED) stock has had a tumultuous trading history and investors want to know if is a good buy for their portfolios today.

Shiny Health appoints interim CEO after Nadeau’s resignation

Shiny Health & Wellness has appointed Meris Kott as the cannabis company's interim CEO after the resignation of Michael Nadeau.